Atopic Dermatitis (Eczema)
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the safety and effectiveness of baricitinib in people with eczema.
The results of this study are not yet available.
Your participation could last up to 28 weeks and include 8 visits to the study center.
Here you can find out a bit more about the requirements for volunteers who took part in this study
Participant must have moderate-to-severe Atopic Dermatitis (AD)
Participant must have a history of inadequate clinical response to other eczema treatments
Participant must agree to use adequate contraception
Female participant must not be pregnant or nursing
Participant must not have skin conditions such as psoriasis or lupus erythematosus or a skin disease that requires frequent hospitalizations or IV treatment
Participant must not have compromised immunity
Participant must not have active or latent tuberculosis, HIV, Hepatitis B, Hepatitis C or chronic liver disease